Arslan Gürcan Dogukan, Guven Dilek, Alkan Abdurrahman Alpaslan, Kacar Hakan, Demir Mehmet
Department of Opthalmology, Şişli Hamidiye Etfal Training and Research Hospital , İstanbul , Turkey.
Cutan Ocul Toxicol. 2019 Dec;38(4):344-348. doi: 10.1080/15569527.2019.1616749. Epub 2019 May 30.
To evaluate short term changes in anterior chamber depth (ACD), central corneal thickness (CCT), intraocular pressure (IOP), and corneal endothelial cell density (ECD) after intravitreal anti-vascular endothelial growth factor (VEGF) injections. A total of 100 eyes from 100 patients, who were naive for intravitreal injection treatment, were included in this retrospective study. Patients who received only a single type of intravitreal anti-VEGF injections (bevacizumab, ranibizumab, or aflibercept) for two consecutive months were examined. ACD, CCT, IOP, and ECD measurements were taken at pre-injection and one month after the first and second injections and were compared. The mean corneal ECD for all eyes and phakic eyes was significantly lower one month after the first ( = 0.041 and = 0.047, respectively) and second injections ( = 0.013 and = 0.034, respectively) compared to the values at pre-injection levels. Similarly, the mean ACD of all eyes and phakic eyes was significantly lower one month after the first ( < 0.001 and < 0.001, respectively) and second injections ( < 0.001 and < 0.001, respectively) compared to the values at pre-injection levels. However, there was no significant difference in pseudophakic eyes one month after the first and second injections (ECD, = 0.28 and = 0.23; ACD, = 0.75 and = 0.71, respectively). There was no significant change in IOP and CCT values at pre-injection and one month after the first and second injections for all eyes and for both the phakic and pseudophakic eyes. After the anti-VEGF injections, IOP and CCT values were not significantly changed and were similar in all eyes and phakic eyes; however, in these groups, there was a small but statistically significant decrease in ACD and ECD. On the contrary, there was no significant difference in pseudophakic eyes. Clinicians performing intravitreal injections must be aware of these associations for a better understanding of ACD and ECD changes in phakic eyes.
评估玻璃体内注射抗血管内皮生长因子（VEGF）后前房深度（ACD）、中央角膜厚度（CCT）、眼压（IOP）和角膜内皮细胞密度（ECD）的短期变化。本回顾性研究纳入了100例首次接受玻璃体内注射治疗的患者的100只眼。连续两个月仅接受单一类型玻璃体内抗VEGF注射（贝伐单抗、雷珠单抗或阿柏西普）的患者接受检查。在注射前、首次注射后1个月和第二次注射后1个月测量ACD、CCT、IOP和ECD，并进行比较。与注射前水平相比，所有眼和有晶状体眼在首次注射后1个月（分别为P = 0.041和P = 0.047）和第二次注射后1个月（分别为P = 0.013和P = 0.034）的平均角膜ECD显著降低。同样，所有眼和有晶状体眼在首次注射后1个月（分别为P < 0.001和P < 0.001）和第二次注射后1个月（分别为P < 0.001和P < 0.001）的平均ACD与注射前水平相比显著降低。然而，在首次和第二次注射后1个月，人工晶状体眼的ECD（P = 0.28和P = 0.23）和ACD（P = 0.75和P = 0.71）无显著差异。所有眼以及有晶状体眼和人工晶状体眼在注射前、首次注射后1个月和第二次注射后1个月的IOP和CCT值无显著变化。抗VEGF注射后，IOP和CCT值无显著变化，在所有眼和有晶状体眼中相似；然而，在这些组中，ACD和ECD有小幅但具有统计学意义的降低。相反，人工晶状体眼无显著差异。进行玻璃体内注射的临床医生必须了解这些关联，以便更好地理解有晶状体眼中ACD和ECD的变化。
